All News

Article

Day 1 Report from ACR21

Jack Cush, MD

The first full day of Abstracts and Presentations from ACR Convergence, was full of highly engaging sessions, quality posters and unique presentations. To hear more about the best of the best, I would encourage you to look at our Day 1 Recap Video and Day 1 ACR Best Abstracts. Here are a few of my favorites from the first day.

Eric Dein Tweet
ericdeinmd
#ACR21 Abs#1225: B/L Extracell Matrix Biomarkers predict ABA response in MTX-naive, +ACPA early RA ⭐️ECM biomarkers predict SDAI remission or DAS28 w ABA+MTX vs PBO+MTX. ⭐️⬆️CTX1 biomarker predicts efficacy endpts for ABA+MTX https://t.co/7wHQefb5D4 @Rheumnow
Mrinalini Dey Tweet
DrMiniDey
Wk 12 disease activity predicts wk 24/26 remission/low disease activity with #upadacitinib 15mg in MTX-naïve or inadequate responders to MTX and/or TNFi pts. ≥50% improvement in SJC/TJC at Wk 12 was assoc with wk 24/26 remission/low disease activity. Abs#1237 #ACR21 @RheumNow https://t.co/PAaCe5MAcu
Aurelie Najm Tweet
AurelieRheumo
Ultrasound in CSA patients: Retro US cohort 110pts 28.2% w/ 💥Power Doppler synovitis. 36.8% at 6mo evolved to RA among which 100% PD+ vs 25% PD- PD + predicts evolution to clinical RA (OR 13.1; CI 1.07-161.04) Easier and less invasive than MRI! #Abstr1525 #ACR21 @RheumNow https://t.co/MkhWTvnv3L
Akhil Sood MD Tweet
AkhilSoodMD
Abst 0789 Baker & colleagues examined adipokine levels in association with disease activity in RA patients - Patients with high levels of adipokines less likely to achieve low disease activity & remission - These patients more likely to escalate to b/tsDMARDs #ACR21 @RheumNow https://t.co/1xlO4W9q9v
Akhil Sood MD Tweet
AkhilSoodMD
Another exciting day at #ACR21 and covering for @RheumNow Also presented my poster (Abstr 0587) DMARD Use in Medicare Patients with #RheumatoidArthritis and Risk of Long-Term Opioid Use - DMARD users showed lower odds of long term opioid use compared to non-DMARD users https://t.co/2XZgYY8ORg
David Liew Tweet
drdavidliew
We know we're all not as great at treat-to-target in RA as we should be. If we want to get fit, we join a group class. If we want to study, we join a study group. Why not the same with TTT, to motivate us to our best? Virtual learning collaboratives 👏 #ACR21 ABST0815 @RheumNow https://t.co/siVOyKjPNx
TheDaoIndex Tweet
KDAO2011
Dr. R Thomas note that even if you have RA, it's not too late to improve your lifestyle to be healthier. This will help with the mgment of the dz. 2/2 @rheumnow #ACR21
Rheum Cat Tweet
rheum_cat
Ethnic disparities in pts with RA & CVD - paucity of evidence in published lit Need to improve study inclusion, diversity to improve quality of care #ACR21 https://t.co/sWKcHugU9W
David Liew Tweet
drdavidliew
In pts w/o RF, liver bx prev suggestd if lifetime cumulative MTX dose was 1-1.5g, then 3.5-4g. All pts in centre offered Fibroscan liver stifness associations: - age, BMI - not cumulative MTX dose maybe survival bias, but what we're doing now is fine! #ACR21 ABST0786 @RheumNow https://t.co/I6IhS3jhmC
Meral K. El Ramahi, MD Tweet
MeralElRamahiMD
Does concomitant SJS affect tx effectiveness in RA? Abst#0839 suggest yes! ➡️RA+SjS have an inferior response to TNFi than RA patients w/o SjS BUT, RA/SJS pts w/ longer RA dz duration & ↑ DAS28 + HAQ-scores. What's your clinical experience with this? #ACR21 @Rheumnow https://t.co/TIc3raMOSJ
Meral K. El Ramahi, MD Tweet
MeralElRamahiMD
Abst#0572: In US veterans w/ RA followed for 17 yrs, several cytokines+chemokines ⭐️Associated w/ ↑ risk of incident MACE independent of typical CVD RF & RA activity & ⭐️Predicted MACE even if in LDA/remission WOW! We need to do better @ CVD risk strat! #ACRBest @RheumNow https://t.co/J74rRa9EQE
×